TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
LBT Innovations Limited ( (AU:CC5) ) has issued an announcement.
Clever Culture Systems Ltd has successfully validated a new APAS® contact plate analysis module, expanding its market potential in the pharmaceutical industry. This development allows the APAS® Independence to automate most environmental monitoring tests in sterile drug manufacturing, enhancing its competitive edge and increasing revenue opportunities. The validation achieved a 0% false negative rate, crucial for customer confidence, and is expected to accelerate adoption among pharmaceutical manufacturers. The launch of this module positions CCS as a leader in comprehensive environmental monitoring solutions, with significant sales opportunities anticipated from existing and new customers.
More about LBT Innovations Limited
Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the company has developed the Automated Plate Assessment System (APAS® Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. The technology is the only US FDA-cleared AI technology for automated culture plate reading and is sold to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories.
Average Trading Volume: 2,135,512
Technical Sentiment Signal: Buy
Current Market Cap: A$63.52M
For an in-depth examination of CC5 stock, go to TipRanks’ Overview page.